Printer Friendly

Sanofi to expand vaccine manufacturing site in Val de Reuil, France.

M2 PHARMA-October 12, 2017-Sanofi to expand vaccine manufacturing site in Val de Reuil, France

(C)2017 M2 COMMUNICATIONS

French multinational pharma company Sanofi (EPA: SAN) is set to expand its vaccine manufacturing site in Val de Reuil, France, the company said on Thursday.

In a move expected to solidify its position as one of the world's leading seasonal flu vaccine providers, Sanofi will invest some EUR170m into the site to help it deliver VaxigripTetra to up to 70 countries in six continents.

The newly released quadrivalent influenza vaccine contains two A strains and two B strains of influenza virus, which the World Health Organisation recommends.

"Influenza continues be a major public health problem around the world, causing serious complications, hospitalisations and deaths, mostly for certain high-risk individuals," said David Loew, executive vice president of Sanofi and head of Sanofi Pasteur.

"As a global leader in flu vaccines, this expansion reinforces Sanofi Pasteur's ability to tackle this underestimated health challenge."

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EUFR
Date:Oct 12, 2017
Words:170
Previous Article:Harbour BioMed licenses transgenic platform to Innovent Biologics.
Next Article:Targovax ASA announces one-year data for modified cohort of TG01 trial.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters